Sensei Biotherapeutics (NASDAQ:FTH) Upgraded by Guggenheim to Strong-Buy Rating

by · The Markets Daily

Guggenheim upgraded shares of Sensei Biotherapeutics (NASDAQ:FTH – Free Report) to a strong-buy rating in a research report sent to investors on Tuesday morning,Zacks reports.

Other equities research analysts have also issued reports about the company. Cantor Fitzgerald restated an “overweight” rating on shares of Sensei Biotherapeutics in a research note on Thursday, June 4th. Citizens Jmp assumed coverage on Sensei Biotherapeutics in a research note on Monday, July 20th. They set an “outperform” rating and a $51.00 price objective for the company. Needham & Company LLC assumed coverage on shares of Sensei Biotherapeutics in a research note on Friday, August 21st. They set a “buy” rating and a $56.00 target price on the stock. JonesTrading began coverage on shares of Sensei Biotherapeutics in a research report on Tuesday, August 4th. They issued a “buy” rating and a $55.00 price target for the company. Finally, Raymond James Financial began coverage on shares of Sensei Biotherapeutics in a research note on Friday, July 31st. They issued an “outperform” rating and a $56.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $56.25.

Read Our Latest Stock Report on FTH

Sensei Biotherapeutics Trading Down 3.2%

Sensei Biotherapeutics stock opened at $34.24 on Tuesday. Sensei Biotherapeutics has a 52-week low of $7.45 and a 52-week high of $42.14. The company has a market cap of $884.76 million, a P/E ratio of -0.24 and a beta of -0.28. The company’s 50-day moving average price is $31.94.

Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($5.04) by $2.20. On average, equities research analysts forecast that Sensei Biotherapeutics will post -13.69 EPS for the current fiscal year.

Insider Activity at Sensei Biotherapeutics

In other Sensei Biotherapeutics news, CFO Brian C. Stephenson purchased 5,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were bought at an average cost of $23.50 per share, with a total value of $117,500.00. Following the acquisition, the chief financial officer owned 46,688 shares in the company, valued at approximately $1,097,168. This trade represents a 11.99% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Anand Kiran Parikh purchased 2,806 shares of the company’s stock in a transaction on Monday, June 22nd. The stock was acquired at an average price of $19.76 per share, with a total value of $55,446.56. Following the completion of the purchase, the chief executive officer directly owned 764,234 shares in the company, valued at $15,101,263.84. This trade represents a 0.37% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 49,494 shares of company stock worth $1,188,822 in the last three months. 7.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Sensei Biotherapeutics

Several institutional investors have recently bought and sold shares of the stock. Vivo Capital LLC purchased a new stake in Sensei Biotherapeutics in the 1st quarter worth $22,758,000. Stempoint Capital LP purchased a new position in shares of Sensei Biotherapeutics during the first quarter valued at about $4,188,000. Alyeska Investment Group L.P. purchased a new position in shares of Sensei Biotherapeutics during the second quarter valued at about $3,610,000. Bank of America Corp DE increased its holdings in shares of Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Sensei Biotherapeutics by 178.2% in the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after buying an additional 20,525 shares in the last quarter. 10.50% of the stock is owned by hedge funds and other institutional investors.

About Sensei Biotherapeutics

(Get Free Report)

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei’s technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.

Further Reading